Date: May 31, 2026

Financial Results (Standalone & Consolidated)

Standalone Performance (₹ crore)

Q4 FY26:

  • Net Sales: ₹44.45 (up 16.55% from ₹38.14 in Q4 FY25)
  • EBITDA: ₹8.78 (down 61.94% from ₹23.07 in Q4 FY25)
  • EBITDA Margin: 19.75% (down 4074 bps from 60.49%)
  • PAT: -₹8.10 (down 574.30% from ₹1.71 profit in Q4 FY25)
  • PAT Margin: -18.23% (down 2271 bps from 4.48%)

Full Year FY26:

  • Net Sales: ₹183.38 (up 19.53% from ₹153.41 in FY25)
  • EBITDA: ₹49.40 (up 8.64% from ₹45.47 in FY25)
  • EBITDA Margin: 26.94% (down 270 bps from 29.64%)
  • PAT: ₹13.98 (down 12.85% from ₹16.04 in FY25)
  • PAT Margin: 7.62% (down 283 bps from 10.45%)

Consolidated Performance (₹ crore)

Q4 FY26:

  • Net Sales: ₹67.31 (down 10.52% from ₹75.22 in Q4 FY25)
  • EBITDA: ₹8.78 (down 61.94% from ₹23.07 in Q4 FY25)
  • EBITDA Margin: 13.04% (down 1763 bps from 30.67%)
  • PAT: -₹15.69 (down 253.16% from -₹4.44 loss in Q4 FY25)
  • PAT Margin: -23.30% (down 1740 bps from -5.91%)

Full Year FY26:

  • Net Sales: ₹286.13 (down 7.19% from ₹308.30 in FY25)
  • EBITDA: ₹71.50 (down 25.82% from ₹96.39 in FY25)
  • EBITDA Margin: 24.99% (down 628 bps from 31.26%)
  • PAT: -₹27.39 (down 5757.92% from ₹0.48 profit in FY25)
  • PAT Margin: -9.57% (down 973 bps from 0.16%)

Segment Performance (₹ crore)

SaaS Business:

  • Q4 FY26 Revenue: ₹36.94 (up 6.67% from ₹34.63 in Q4 FY25)
  • Q4 FY26 EBIT: -₹10.63
  • FY26 Revenue: ₹153.94 (up 15.42% from ₹133.37 in FY25)
  • FY26 EBIT: ₹13.18 (down from ₹19.84 in FY25)

ITES Business:

  • Q4 FY26 Revenue: ₹3.68
  • Q4 FY26 EBIT: ₹0.37
  • FY26 Revenue: ₹10.07
  • FY26 EBIT: ₹1.01

IDC & IT Services:

  • Q4 FY26 Revenue: ₹10.86 (up 78.26% from ₹6.09 in Q4 FY25)
  • Q4 FY26 EBIT: ₹0.14 (improved from -₹2.11 loss in Q4 FY25)
  • Q4 FY26 EBIT Margin: 1.31% (improved from -34.62%)
  • FY26 Revenue: ₹40.37 (down 29.55% from ₹57.30 in FY25)
  • FY26 EBIT: -₹2.37 (down from ₹18.59 profit in FY25)
  • FY26 EBIT Margin: -5.88% (down from 32.45%)

Healthcare:

  • Q4 FY26 Revenue: ₹14.49 (down 44.42% from ₹26.07 in Q4 FY25)
  • Q4 FY26 EBIT: -₹0.60 (worsened from -₹0.45 loss in Q4 FY25)
  • Q4 FY26 EBIT Margin: -4.15% (down from -1.74%)
  • FY26 Revenue: ₹79.99 (down 23.20% from ₹104.15 in FY25)
  • FY26 EBIT: ₹0.15 (improved from -₹0.88 loss in FY25)
  • FY26 EBIT Margin: 0.18% (improved from -0.84%)

Key Operational Highlights

Exceptional Item

  • The company recorded a one-time, fully-provided write-off of ₹8.43 crore (USD 890,530) on receivable from QC Holdings, one of its major SaaS customers, after following due recovery procedures.
  • Excluding this write-off, underlying operating performance remained robust across core businesses.

SaaS Business Update

  • Revenue growth driven by continued demand for software solutions and recurring revenue model.
  • Revenue contributions from recently acquired clients Check 'n Go and MoneyTree Inc. have reached stable run-rate and will continue as recurring revenue streams.
  • Underlying operating performance remained strong excluding the one-time write-off.

IDC & IT Services Challenges

  • Significant decline in onshore revenue due to stricter visa regime.
  • Reduction in average billing rates.
  • Revenue mix shifted substantially toward offshore revenue due to uncertainties surrounding U.S. visa environment.
  • Company transitioning existing clients to offshore delivery models to ensure service continuity and optimize operational efficiency.

Healthcare Business Restructuring

  • Performance decline attributed to operational challenges.
  • Newly appointed management team focused on operational excellence.
  • Strengthened business development function aimed at driving growth.
  • In March 2026, promoter acquired 49% stake in Virinchi Health Care Private Limited through fresh infusion of funds, transitioning it from wholly owned subsidiary to significant subsidiary.

Outlook

With SaaS franchise on stable recurring run-rate following client additions, new senior doctor team driving hospital turnaround, and fresh promoter capital infused into healthcare subsidiary, the Company enters FY27 structurally stronger and well-positioned for return to profitable growth.